AKER BIOMARINE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.3 NOK | -1.79% |
|
+0.56% | +55.00% |
| 04-26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company sustains low margins.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 260.76 and 327.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Fishing & Farming
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +55.00% | 566M | B- | ||
| +12.78% | 3.29B | B | ||
| -95.58% | 1.61B | - | C+ | |
| -0.48% | 1.61B | C | ||
| -2.37% | 1.25B | D+ | ||
| -2.40% | 1.22B | B | ||
| -.--% | 1.22B | - | - | |
| -11.54% | 1.21B | - | - | |
| -10.44% | 1.2B | - | ||
| 0.00% | 1.19B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AKBM Stock
- Ratings Aker BioMarine
